XML 51 R34.htm IDEA: XBRL DOCUMENT
v3.23.3

License and Collaboration Agreements (Details) € in Millions |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 05, 2022 USD ($) | Dec. 14, 2020 USD ($) | Oct. 06, 2020 USD ($) | Nov. 01, 2019 USD ($) | Oct. 31, 2023 USD ($) | Jul. 31, 2023 USD ($) | Jan. 31, 2022 USD ($) | Oct. 31, 2021 USD ($) | Feb. 28, 2021 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2020 USD ($) | Sep. 30, 2023 EUR (€)
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  | $ 45,977,000 | $ 63,641,000 | $ 188,253,000 | $ 180,968,000 |  |  |
Equity method investment |  |  |  |  |  |  |  |  |  | 5,365,000 |  | 5,365,000 |  | $ 12,817,000 |  |
Collaboration revenue - related party |  |  |  |  |  |  |  |  |  | 43,000 | 49,000 | 139,000 | 196,000 |  |  |
Payments for investments |  |  |  |  |  |  |  |  |  |  |  | $ 369,927,000 | 200,318,000 |  |  |
Pfizer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty obligation period from date of first sale |  |  |  |  |  |  |  |  |  |  |  | 12 years |  |  |  |
University Of Texas MD Anderson Cancer Center |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000,000 |
Collaboration agreement term |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |
Committed funding |  |  | $ 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
University Of Texas MD Anderson Cancer Center | Subsequent Event |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, upfront payment |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |
Allogene Overland, Allogene Overland BioPharm (HK) Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue - related party |  |  |  |  |  |  |  |  |  | 100,000 | 100,000 | $ 100,000 | 200,000 |  |  |
Reduction to research and development expense |  |  |  |  |  |  |  |  |  | 0 | 300,000 | 100,000 | 600,000 |  |  |
Notch Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity method investment, impairment |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |
Antion |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |
Warrants and rights outstanding |  |  |  |  |  | 3,000,000 |  |  |  |  |  |  |  |  |  |
Investment in equity securities |  |  |  |  |  | 1,000,000 |  |  |  | 4,000,000 |  | 4,000,000 |  | 3,000,000 |  |
Research and development | University Of Texas MD Anderson Cancer Center |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration arrangement, expense |  |  |  |  |  |  |  |  |  | 200,000 | 200,000 | $ 1,200,000 | 1,100,000 |  |  |
Research and development | Notch Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, company's right to terminate, period to provide written notice |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |
Collaboration arrangement, expense |  |  |  |  |  |  |  |  |  | 0 | 1,000,000 | $ 1,800,000 | 2,800,000 |  |  |
Notch Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity method investment |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |
Payments for additional investment in interest |  |  |  |  |  |  |  | $ 1,800,000 | $ 15,900,000 |  |  |  |  |  |  |
Equity method investment, impairment |  |  |  |  |  |  |  |  |  | 3,000,000 |  | 3,000,000 |  | 0 |  |
Notch Therapeutics, Inc. | Voting Interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  |  |  |  |  |  |  | 23.00% | 20.70% |  |  |  |  |  |  |
Allogene Overland |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity method investment |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  | 0 |  |
Ownership percentage |  | 49.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allogene Overland | Overland Pharmaceuticals Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership percentage |  | 51.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research Collaboration and License Agreement | Cellectis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum payments required per product against selected target |  |  |  |  |  |  |  |  |  |  |  | 185,000,000 |  |  |  |
Research Collaboration and License Agreement | Notch Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payable |  |  |  |  |  |  |  |  |  | 7,250,000 |  | 7,250,000 |  |  |  |
License and Collaboration Agreement | Notch Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, upfront payment |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Corporate Joint Venture | Allogene Overland | Overland Pharmaceuticals Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and quarterly cash payments |  | $ 117,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Joint venture capital support payments |  | 40,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Corporate Joint Venture | Allogene Overland | Allogene Overland, Allogene Overland BioPharm (HK) Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payments |  | 40,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, upfront payment |  | $ 40,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Antion Collaboration Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, upfront payment | $ 3,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration arrangement, expense |  |  |  |  |  |  |  |  |  | 0 | 600,000 | 1,800,000 | 4,500,000 |  |  |
Prior investment obligation |  |  |  |  |  | 3,000,000 |  |  |  |  |  |  |  |  |  |
Costs incurred related to milestone achievement |  |  |  |  |  |  |  |  |  | 400,000 | 0 | 400,000 | 0 |  |  |
Antion Collaboration Agreement | Current Accrued and Other Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration arrangement, expense |  |  |  |  |  |  |  |  |  |  |  | 400,000 |  | 500,000 |  |
Antion Collaboration Agreement | Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments for investments |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |
Preferred stock investment payable |  |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |  |  |  |
Antion Collaboration Agreement, Milestone Achievement One |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payable | 35,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Antion Collaboration Agreement, Milestone Achievement Two |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payable | $ 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Contribution Agreement | Pfizer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payments |  |  |  |  |  |  |  |  |  |  |  | 325,000,000 |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 | 0 |  |  |
Asset Contribution Agreement | Minimum | Pfizer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payments |  |  |  |  |  |  |  |  |  |  |  | 30,000,000 |  |  |  |
Asset Contribution Agreement | Maximum | Pfizer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payments |  |  |  |  |  |  |  |  |  |  |  | 60,000,000 |  |  |  |
Aggregate potential regulatory and development milestones |  |  |  |  |  |  |  |  |  |  |  | 840,000,000 |  |  |  |
Pre-Clinical Development Milestone | Research Collaboration and License Agreement | Cellectis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 | 0 |  |  |
Pre-Clinical Development Milestone | Maximum | License and Collaboration Agreement | Notch Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payments |  |  |  |  |  |  |  |  |  |  |  | 4,000,000 |  |  |  |
Clinical, Regulatory, and Commercial Milestone | Maximum | License and Collaboration Agreement | Notch Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payments |  |  |  |  |  |  |  |  |  |  |  | 283,000,000 |  |  |  |
Development and Sales | Maximum | Research Collaboration and License Agreement | Cellectis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payments |  |  |  |  |  |  |  |  |  |  |  | $ 2,800,000,000 |  |  |  |
Related Party | Allogene Overland, Allogene Overland BioPharm (HK) Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net cost recoveries |  |  |  |  |  |  |  |  |  | 0 | 300,000 |  | 600,000 |  |  |
Related Party | License and Collaboration Agreement | Servier |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of development costs payable by the Company |  |  |  |  |  |  |  |  |  |  |  | 60.00% |  |  |  |
Percentage of development cost payable by collaboration partner |  |  |  |  |  |  |  |  |  |  |  | 40.00% |  |  |  |
Net cost recoveries |  |  |  |  |  |  |  |  |  | 100,000 | $ 3,800,000 | $ 400,000 | $ 20,400,000 |  |  |
Due from related parties |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  | $ 1,500,000 |  |
Related Party | Regulatory Milestone | License and Collaboration Agreement | Servier |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone receivable |  |  |  |  |  |  |  |  |  | 42,000,000 |  | 42,000,000 |  |  |  |
Related Party | Regulatory Milestone | Maximum | License and Collaboration Agreement | Servier |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payments |  |  |  |  |  |  |  |  |  |  |  | 137,500,000 |  |  |  |
Related Party | Sales Milestone | License and Collaboration Agreement | Servier |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone receivable |  |  |  |  |  |  |  |  |  | $ 74,500,000 |  | 74,500,000 |  |  |  | € 70.5
Related Party | Sales Milestone | Maximum | License and Collaboration Agreement | Servier |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate potential milestone payments |  |  |  |  |  |  |  |  |  |  |  | $ 78,000,000 |  |  |  |
Cellectis | Research Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, breech of obligation, period to cure |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |
Collaborative agreement, company's right to terminate, period to provide written notice |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |  |  |
Collaborative agreement, option to terminate, period after material breech |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |
Collaborative agreement, option to terminate, period after change in control |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |  |  |

X
- Definition Aggregate potential milestone payable + References No definition available. + Details
Name: | allo_AggregatePotentialMilestonePayable
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate potential milestone payments. + References No definition available. + Details
Name: | allo_AggregatePotentialMilestonePayments
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate potential milestone receivable. + References No definition available. + Details
Name: | allo_AggregatePotentialMilestoneReceivable
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential regulatory and development milestones. + References No definition available. + Details
Name: | allo_AggregatePotentialRegulatoryAndDevelopmentMilestones
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Committed Funding + References No definition available. + Details
Name: | allo_CollaborationAgreementCommittedFunding
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Costs Incurred Related To Milestone Achievement + References No definition available. + Details
Name: | allo_CollaborationAgreementCostsIncurredRelatedToMilestoneAchievement
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration Agreement, Term + References No definition available. + Details
Name: | allo_CollaborationAgreementTerm
Namespace Prefix: | allo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreement, Upfront Payment + References No definition available. + Details
Name: | allo_CollaborationAgreementUpfrontPayment
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Arrangement, Expense + References No definition available. + Details
Name: | allo_CollaborationArrangementExpense
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Agreement, Breech Of Obligation, Period To Cure + References No definition available. + Details
Name: | allo_CollaborativeAgreementBreechOfObligationPeriodToCure
Namespace Prefix: | allo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Company's Right To Terminate, Period To Provide Written Notice + References No definition available. + Details
Name: | allo_CollaborativeAgreementCompanysRightToTerminatePeriodToProvideWrittenNotice
Namespace Prefix: | allo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Option To Terminate, Period After Change In Control + References No definition available. + Details
Name: | allo_CollaborativeAgreementOptionToTerminatePeriodAfterChangeInControl
Namespace Prefix: | allo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Agreement, Option To Terminate, Period After Material Breech + References No definition available. + Details
Name: | allo_CollaborativeAgreementOptionToTerminatePeriodAfterMaterialBreech
Namespace Prefix: | allo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Rights And Obligations, Preferred Stock Investment, Payable + References No definition available. + Details
Name: | allo_CollaborativeArrangementRightsAndObligationsPreferredStockInvestmentPayable
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Rights And Obligations, Prior Investment Obligation, Amount + References No definition available. + Details
Name: | allo_CollaborativeArrangementRightsAndObligationsPriorInvestmentObligationAmount
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Joint Venture Capital Support Payments + References No definition available. + Details
Name: | allo_JointVentureCapitalSupportPayments
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Maximum payments required per product against selected target. + References No definition available. + Details
Name: | allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | allo_MilestonePayments
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage Of Development Cost Payable By Related Party + References No definition available. + Details
Name: | allo_PercentageOfDevelopmentCostPayableByCollaborationPartner
Namespace Prefix: | allo_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Development Cost Payable By The Company + References No definition available. + Details
Name: | allo_PercentageOfDevelopmentCostPayableByTheCompany
Namespace Prefix: | allo_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reduction to Research and Development Expense + References No definition available. + Details
Name: | allo_ReductionToResearchAndDevelopmentExpense
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty Obligation Period From Date Of First Sale + References No definition available. + Details
Name: | allo_RoyaltyObligationPeriodFromDateOfFirstSale
Namespace Prefix: | allo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront and Quarterly Cash Payments + References No definition available. + Details
Name: | allo_UpfrontAndQuarterlyCashPayments
Namespace Prefix: | allo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1 + Details
Name: | us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of investment in equity method investee and investment in and advance to affiliate. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount due from parties in nontrade transactions, classified as other. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_OtherReceivables
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the purchase of all investments (debt, security, other) during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RecoveryOfDirectCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + References No definition available. + Details
Name: | us-gaap_WarrantsAndRightsOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=allo_PfizerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=allo_UniversityOfTexasMDAndersonCancerCenterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=allo_AllogeneOverlandAllogeneOverlandBioPharmHKLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=allo_NotchTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=allo_AntionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | allo_EquityInvestmentBasisAxis=allo_VotingInterestMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=allo_OverlandPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=allo_ResearchCollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=allo_CellectisSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CorporateJointVentureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=allo_OverlandPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=allo_CurrentAccruedAndOtherLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMilestoneAchievementOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=allo_AntionCollaborationAgreementMilestoneAchievementTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=allo_AssetContributionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=allo_PreClinicalDevelopmentMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=allo_ClinicalRegulatoryAndCommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | allo_MilestoneTypeAxis=allo_DevelopmentAndSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=allo_ServierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=allo_SalesMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |